AstraZeneca commits $57.5M to seed Anticalin R&D pact with Pieris, a biotech on a roll
Boston-based Pieris Pharmaceuticals has rolled out its second big-money collaboration in the last four months, this time reeling in Big Pharma player AstraZeneca, which wants to see just how effective the biotech’s protein engineering work can be in treating respiratory diseases.
Pieris $PIRS has been working for years on engineering proteins that are lighter and more versatile than antibodies, so that they can work where antibodies find their entry barred.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.